Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts.

We recently showed that monoclonal antibodies (mAbs) against beta2-microglobulin (beta2M) have a remarkably strong apoptotic effect on myeloma cells. The mAbs induced apoptosis by recruiting major histocompatibility complex (MHC) class I to lipid rafts, activated c-Jun N-terminal kinase (JNK), and inhibited phosphatidylinositol 3-kinase (PI3K)/Akt and extracellular signal-regulated kinase (ERK) pathways. Growth and survival cytokines such as interleukin-6 (IL-6) and insulin-like growth factor-I (IGF-I), which could protect myeloma cells from dexamethasone-induced apoptosis, did not affect mAb-mediated cell death. This study was undertaken to elucidate the mechanisms underlying anti-beta2M mAb-induced PI3K/Akt and ERK inhibition and the inability of IL-6 and IGF-I to protect myeloma cells from mAb-induced apoptosis. We focused on lipid rafts and confirmed that these membrane microdomains are required for IL-6 and IGF-I signaling. By recruiting MHC class I into lipid rafts, anti-beta2M mAbs excluded IL-6 and IGF-I receptors and their substrates from the rafts. The mAbs not only redistributed the receptors in cell membrane, but also abrogated IL-6- or IGF-I-mediated Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3), PI3K/Akt, and Ras/Raf/ERK pathway signaling, which are otherwise constitutively activated in myeloma cells. Thus, this study further defines the tumoricidal mechanism of the mAbs and provides strong evidence to support the potential of these mAbs as therapeutic agents for myeloma.

[1]  G. Morgan,et al.  Essential Role of Caveolae in Interleukin-6- and Insulin-like Growth Factor I-triggered Akt-1-mediated Survival of Multiple Myeloma Cells* , 2003, The Journal of Biological Chemistry.

[2]  G. Freund,et al.  Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226. , 1993, Journal of immunology.

[3]  Sebastian Spindeldreher,et al.  Clustering of MHC–peptide complexes prior to their engagement in the immunological synapse: lipid raft and tetraspan microdomains , 2002, Immunological reviews.

[4]  K. Vanderkerken,et al.  Specific roles for the PI3K and the MEK–ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model , 2004, British Journal of Cancer.

[5]  Michael L. Wang,et al.  Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. , 2006, Cancer cell.

[6]  N. Tsuyama,et al.  Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor alpha [corrected]. , 2003, Blood.

[7]  M. Sporn,et al.  The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. , 2004, Blood.

[8]  N. Tsuyama,et al.  A rapid translocation of CD45RO but not CD45RA to lipid rafts in IL-6-induced proliferation in myeloma. , 2005, Blood.

[9]  S. Rudikoff,et al.  Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. , 2002, Blood.

[10]  J. Mackey,et al.  Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting. , 1999, Seminars in oncology.

[11]  B. Klein.  Update of gp130 cytokines in multiple myeloma , 1998, Current opinion in hematology.

[12]  K. Anderson.  Advances in disease biology: Therapeutic implications , 2001 .

[13]  H. Asaoku,et al.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas , 1988, Nature.

[14]  Z. Estrov,et al.  Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells , 2005, British Journal of Cancer.

[15]  T. Hervig,et al.  Malignancy: Insulin-like Growth Factor-1 (IGF-1) is a Costimulator of the Expansion of Lineage Committed Cells Derived from Peripheral Blood Mobilized CD34+ Cells in Multiple Myeloma Patients. , 1999, Hematology.

[16]  B. Dörken,et al.  PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells , 2004, Leukemia.

[17]  R. Sanyal,et al.  Cholesterol depletion inhibits src family kinase‐dependent calcium mobilization and apoptosis induced by rituximab crosslinking , 2005, Immunology.

[18]  R. Cordera,et al.  IGF-I induces caveolin 1 tyrosine phosphorylation and translocation in the lipid rafts. , 2002, Biochemical and biophysical research communications.

[19]  B. Bonavida,et al.  Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  K. Anderson,et al.  Advances in the biology of multiple myeloma: therapeutic applications. , 1999, Seminars in oncology.

[21]  H. Langen,et al.  Tetraspan microdomains distinct from lipid rafts enrich select peptide–MHC class II complexes , 2002, Nature Immunology.

[22]  J. Epstein,et al.  Consequences of interactions between the bone marrow stroma and myeloma. , 2003, The hematology journal : the official journal of the European Haematology Association.

[23]  T. Roszman,et al.  Lipid rafts in cytokine signaling. , 2004, Cytokine & growth factor reviews.

[24]  F. André,et al.  Membrane rafts segregate pro- from anti-apoptotic insulin-like growth factor-I receptor signaling in colon carcinoma cells stimulated by members of the tumor necrosis factor superfamily. , 2005, The American journal of pathology.

[25]  B. Klein,et al.  Interleukin-6 in human multiple myeloma. , 1995, Blood.

[26]  T. Hervig,et al.  Insulin-like Growth Factor-1 (IGF-1) is a Costimulator of the Expansion of Lineage Committed Cells Derived from Peripheral Blood Mobilized CD34(+) Cells in Multiple Myeloma Patients. , 1999, Hematology.

[27]  S. Pierce.  Lipid rafts and B-cell activation , 2002, Nature Reviews Immunology.

[28]  K. Anderson.  Multiple Myeloma. Advances in disease biology: therapeutic implications. , 2001, Seminars in hematology.

[29]  B. Barlogie,et al.  Interleukin-6 prevents dexamethasone-induced myeloma cell death. , 1994, Blood.

[30]  D. Chauhan,et al.  Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma , 2001, Oncogene.

[31]  J. D. Vos,et al.  Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1 , 2000, Cell Death and Differentiation.

[32]  B. Barlogie,et al.  Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. , 2006, Haematologica.